Gliomas Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Glioma / [M]Glioma NOS

IndicationStatusPhase
DBCOND0032593 (Gliomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01967810ANG1005 in Patients With Recurrent High-Grade GliomaTreatment
NCT00463203Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard TherapyTreatment
NCT00795665Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade GliomaTreatment
NCT01137604A Study in Subjects With Recurrent Malignant GliomaTreatment